ADXN
Addex Therapeutics Ltd
NASDAQ · Healthcare · Biotechnology · CH
$3.72
+0.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 74.0K | 30.0K | 404.1K | 1.6M | 1.4M |
| Cost of Revenue | 270.6K | — | — | — | — |
| Gross Profit | (196.5K) | 30.0K | 404.1K | 1.6M | 1.4M |
| Operating Expenses | |||||
| R&D Expense | 167.0K | 190.2K | 435.2K | 942.7K | 7.9M |
| SG&A Expense | 1.8M | 1.9M | 1.7M | 2.0M | 3.3M |
| General & Admin Expense | 1.8M | 1.9M | 1.7M | 2.0M | 3.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 495.4K | 766.5K | 1.0M | 882.2K | 817.8K |
| Total Operating Expenses | 2.5M | 2.8M | 3.2M | 3.9M | 12.0M |
| Cost and Expenses | 2.8M | 2.8M | 3.2M | 3.9M | 12.0M |
| Operating Income (EBIT) | (2.7M) | (2.8M) | (2.8M) | (2.2M) | (10.5M) |
| Non-Operating | |||||
| Interest Income | 3.00 | — | 9.2K | 64.0K | 29.3K |
| Interest Expense | 4.9K | 2.4K | 3.5K | 21.6K | 48.9K |
| Net Interest Income | (4.9K) | (2.4K) | 5.6K | 42.4K | (19.6K) |
| Other Non-Op Income/Expense | (4.4M) | (4.0M) | (2.2M) | (257.2K) | (263.1K) |
| Non-Operating Income (excl Interest) | 4.4M | 4.0M | 2.2M | 253.3K | 235.1K |
| EBT (Pre-Tax Income) | (7.1M) | (6.8M) | (4.9M) | (2.5M) | (10.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.0M) | (6.7M) | 7.1M | (10.6M) | (20.8M) |
| Earnings from Cont. Ops | (7.1M) | (6.8M) | (4.9M) | (2.5M) | (10.8M) |
| Earnings from Discont. Ops | 114.3K | 114.3K | 12.0M | (8.1M) | (10.0M) |
| Bottom Line Net Income | (7.1M) | (6.7M) | 7.1M | (10.6M) | (20.8M) |
| Per Share | |||||
| Basic EPS | ($6.97) | ($6.88) | $8.40 | ($16.80) | ($55.20) |
| Diluted EPS | ($6.81) | ($6.88) | $8.40 | ($16.80) | ($55.20) |
| Revenue Per Share | $0.05 | $0.03 | $0.49 | $2.60 | $3.78 |
| Shares | |||||
| Basic Shares Outstanding | 1.4M | 935000 | 817606 | 619230 | 376540 |
| Diluted Shares Outstanding | 1.4M | 935000 | 817606 | 619230 | 376540 |
| Profitability Metrics | |||||
| EBITDA | (7.1M) | (6.8M) | (4.6M) | (2.2M) | (10.5M) |
| D&A | 16.2K | 8.5K | 260.1K | 306.0K | 323.1K |
| EBIT | (7.1M) | (6.8M) | (4.9M) | (2.5M) | (10.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026